Skip to main content
ImmunityBio, Inc. logo

ImmunityBio, Inc. — Investor Relations & Filings

Ticker · IBRX ISIN · US45256X1037 LEI · 529900J9XLBR4HFL4B83 US Manufacturing
Filings indexed 519 across all filing types
Latest filing 2026-05-18 Regulatory Filings
Country US United States of America
Listing US IBRX

About ImmunityBio, Inc.

https://immunitybio.com/

ImmunityBio, Inc. is a commercial-stage biotechnology company developing next-generation immunotherapies and vaccines designed to strengthen a patient's own immune system. The company's approach focuses on orchestrating both the innate (natural killer cells) and adaptive (T cells) immune systems to combat cancer and infectious diseases. Its key platforms include the IL-15 superagonist Anktiva® (N-803), engineered natural killer (NK) cell therapies, and adenovirus-vectored vaccines. These therapies are being investigated and applied across a range of difficult-to-treat cancers, such as bladder, lung, and pancreatic cancers, as well as infectious diseases like HIV. The company's goal is to create durable, complete responses by treating the host's immune system rather than just the disease.

Recent filings

Filing Released Lang Actions
8-K
Regulatory Filings
2026-05-18 English
10-Q - ImmunityBio, Inc. (0001326110) (Filer)
Interim / Quarterly Report
2026-05-07 English
8-K - ImmunityBio, Inc. (0001326110) (Filer)
Regulatory Filings
2026-05-07 English
8-K - ImmunityBio, Inc. (0001326110) (Filer)
Regulatory Filings
2026-04-09 English
8-K - ImmunityBio, Inc. (0001326110) (Filer)
Regulatory Filings
2026-04-06 English
8-K - ImmunityBio, Inc. (0001326110) (Filer)
Regulatory Filings
2026-03-31 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.